Bildnachweis: iOmx therapeutics AG, iOmx Therapeutics AG.
The first generation of cancer immunotherapies has revolutionised oncology, yet many solid tumours remain resistant. Founded in 2016 as a spin-out from the German Cancer Research Center (DKFZ), iOmx Therapeutics develops therapies targeting mechanisms that enable tumours to evade the immune system. Backed by a transatlantic investor syndicate, the company has evolved from a target-discovery pioneer into a clinical-stage multi-asset biotech.
Although checkpoint inhibitors such as PD-1 and CTLA-4 blockers have transformed cancer treatment, only a minority of patients achieve durable benefits. iOmx focuses on previously unexplored tumour immune-evasion mechanisms, combining tumour immunology, antibody engineering, translational research and clinical development to advance monoclonal and bispecific antibodies as well as T cell engagers. “At iOmx, we select our drug candidates with the goal of demonstrating meaningful monotherapy efficacy in clinical studies. To achieve this, we focus on highly relevant targets and develop multispecific drug candidates that are designed to provide more than one mode of action through dual targeting. From the very beginning of each drug development program, we also define a biomarker-supported patient enrichment strategy to maximize the likelihood of clinical benefit,” says CEO Dr Apollon Papadimitriou.

A Diversified Biologics Pipeline
A key programme is IOMX-0675, a dual-targeting antibody against LILRB1 and LILRB2, complementary inhibitory receptors involved in regulating innate and adaptive immune cells. By blocking both receptors, the candidate aims to restore anti-tumour immune activity in cancers that respond inadequately to established checkpoint therapies. The wider pipeline includes bispecific antibodies and T cell engagers designed to recruit immune cells to cancer cells, activate them locally or address suppressive signals. “We are building a unique, risk-balanced portfolio that combines programmes against clinically validated as well as novel targets with the goal of developing highly differentiated, powerful and safe therapies. Our strategy is to advance selected programmes in-house while pursuing early strategic partnerships with pharma for other assets,” says Papadimitriou. “When we prioritise programmes, we look at several factors, including the unmet medical need, market opportunity, probability of technical success, the competitive landscape, and the cost and speed to key value inflection points. At the same time, scientific differentiation is a key criterion.”
‘Smart Money’ on the Cap Table

iOmx has secured a transatlantic investor syndicate. Following a €40 million Series A, the company raised a €65 million Series B co-led by Munich-based MIG Capital AG and ATHOS, the family office of the Strüngmann brothers. For investors, a key differentiator is iOmx’s strategy of targeting immune-evasion mechanisms that are orthogonal to established immuno-oncology pathways. Its pipeline combines validated targets with best-in-class potential and novel targets with first-in-class potential, creating what Dr Matthias Kromayer, Managing Partner at MIG Capital and Supervisory Board Member at iOmx, describes as a risk-balanced profile with multiple value inflection points and significant upside. “Successful programmes could become backbone therapies in major solid tumors,” he says.




